Riboflavin-5-Phosphate and Magnesium: The Second Step of FAD Synthesis Most B2 Supplements Leave Out

Short answer: Vitamin B2 becomes biologically useful through two enzymatic steps. Riboflavin kinase converts riboflavin to FMN, and then FAD synthase converts FMN to FAD, the coenzyme form that flavoproteins actually use. Enzyme studies document that this second reaction requires ATP together with magnesium (Mg²⁺) as a coordinated cofactor. Riboflavin-5′-phosphate (R5P) supplements supply an activated flavin and address the substrate side of the pathway. They do not supply the magnesium the second step draws on. Whether magnesium availability limits FAD synthesis in healthy, well-nourished adults has not been tested in a clinical trial, so pairing R5P with a magnesium cofactor dose is a formulation rationale drawn from enzymology, not a demonstrated outcome.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

You did the homework. You moved off cheap riboflavin and onto R5P, the activated coenzyme form, and you paid the premium that came with it. You stayed consistent for weeks. And the results still would not hold steady. Better some days. Barely noticeable others. Expensive urine with benefits you could not predict.

That inconsistency probably is not your metabolism being stubborn. There is a plausible biochemical reason worth understanding: FAD synthase requires magnesium-bound ATP to convert FMN to FAD, a requirement documented in enzyme studies. Most single-ingredient R5P products on the market do not include magnesium, and it is worth checking your own label.

What we know, and what we don’t

Because this distinction runs through the whole guide, here it is once, plainly, rather than repeated at every turn:

• Documented at the enzyme level: FAD synthase requires ATP and Mg²⁺ to convert FMN to FAD. Riboflavin’s role as the precursor of FMN and FAD is established nutrition science.
• Not established: that magnesium availability is a limiting factor for FAD synthesis in healthy, well-nourished adults, or that supplying a magnesium cofactor dose alongside R5P changes FAD status or how you feel.
• Not tested: BioActive Vitamin B2™ has not been studied as a finished product in a clinical trial. Everything below describes the biochemistry the formula is built on and the specifications it is made to. Individual responses vary.

Triquetra’s Complete Cofactor Activation System™ pairs R5P with a magnesium cofactor dose and D-ribose in a single targeted B2 capsule, a combination we are not aware of in other single-B2 products as of August 2026.

Riboflavin, magnesium, and D-ribose each play established roles in normal cellular energy metabolism. Because riboflavin is water-soluble and not stored in quantity, consistent daily intake is what maintains flavin status.*

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

What’s Inside BioActive Vitamin B2™?

R5P, a magnesium cofactor dose, and D-ribose. The formulation is built around what FAD synthesis requires at the enzyme level rather than around what looks good on an ingredient label.

BioActive Vitamin B2™ is a single B vitamin supplement developed by Triquetra Health for health-conscious individuals ages 30–55 who take targeted supplements rather than multivitamins, and who have dealt with inconsistent B vitamin activation from incomplete cofactor support with standard riboflavin and isolated R5P products. The formula combines:

• 137 mg Riboflavin-5′-Phosphate, providing 100 mg of riboflavin activity at ≥73% riboflavin content
• 278 mg magnesium bisglycinate, a water-soluble amino-acid chelate included as a cofactor dose rather than as a magnesium repletion dose (see the Supplement Facts panel for the declared elemental magnesium per serving)
• 250 mg D-ribose at ≥98% purity

Together these make up the proprietary Complete Cofactor Activation System™, which supplies substrate, enzymatic cofactor, and ATP substrate in one capsule rather than substrate alone.

The product undergoes third-party testing for potency (95–105% of label claim), purity (elemental contaminants against USP ⟨2232⟩ limits for dietary supplements), and microbiological safety, and it is manufactured in a cGMP-compliant, FDA-registered facility (21 CFR Part 111). cGMP compliance and facility registration are manufacturing requirements, not FDA approval or endorsement of this product.

[Learn how the system works: link to be added]

Why Doesn’t Upgrading to R5P Always Give Consistent Results?

You are not the person grabbing whatever is cheapest. You read labels. You know the difference between activated and precursor vitamin forms. Once you learned that riboflavin has to be converted before it is functional, you went looking for the activated version, found R5P, and paid three times more, because quality matters to you.

You already understand something most supplement buyers never pick up: form shapes bioavailability, precursor forms carry real conversion variability, and premium ingredients earn their price when the science backs them up.

What nobody in this industry mentioned is that form is only half the equation.

So the frustration is not random. You track your protocol. You know which days your energy holds: sharp through the afternoon, clear through the 4 PM meeting that usually kicks off your mental slide. You also know the days your B2 seems to do nothing at all, same dose, same premium product. There is no pattern you can pin down. Good sleep, bad sleep. Busy weeks, recovery weeks. None of it lines up with anything you control.

Here is one biochemical possibility. Even the best R5P product supplies substrate for only the first half of FAD synthesis. The second step, FMN to FAD, is catalyzed by an enzyme that draws on magnesium and ATP. Whether that step is a meaningful bottleneck for healthy, well-nourished adults has not been tested in a clinical trial, so treat it as a rationale rather than an explanation of your particular results.

The idea behind this formula is not a better form of B2. It is pairing the activated form with the magnesium cofactor and ATP substrate the second step draws on, so the full pathway has what the enzymology describes.

How Do Standard Riboflavin, High-Dose B2, R5P, and B-Complex Differ?

You have probably worked through each of these categories, and each one has a real advantage. Here is what each actually contains, and where the FAD-synthesis rationale says a gap sits.

Standard riboflavin and generic B-complex vitamins are easy to find and priced right for basic deficiency prevention. What they do not contain is a cofactor for the FMN-to-FAD step: FAD synthase needs magnesium-bound ATP regardless of how much riboflavin substrate is present. That is the rationale for coordinating substrate, cofactor, and ATP support rather than supplying substrate alone.

Isolated R5P products supply the activated flavin form. What they typically do not include is the magnesium cofactor for the second enzymatic step, so the substrate half is covered and the cofactor half is left to whatever your diet and status provide. BioActive Vitamin B2™ includes both the activated form and a catalytic magnesium dose, on that enzymatic rationale.

B-complex multivitamins are convenient. Compared with a targeted B2, they generally contain a lower B2 dose (often 25–50 mg of riboflavin, the unphosphorylated precursor, versus 100 mg of riboflavin activity from R5P here), no magnesium cofactor for FAD synthesis, and additional B vitamins you may not be targeting. On that last point: long-term high-dose vitamin B6 has been associated with peripheral neuropathy, and the Tolerable Upper Intake Level is 100 mg/day for adults (NIH ODS). The European Food Safety Authority set a lower limit of 12 mg/day for adults in 2023. A targeted single-B2 avoids stacking B vitamins you do not need.

The through-line across categories is the same design question: substrate plus cofactor plus ATP, arriving together, versus substrate alone. Complete Cofactor Activation System™ is Triquetra’s attempt to treat FAD synthesis as a coordinated system rather than a single ingredient.

 

How Does the Body Convert Riboflavin into FAD?

The distinction the whole approach rests on is this: you do not run on riboflavin. You run on FAD, the active coenzyme form that appears in dozens of enzymatic reactions, including several in cellular energy metabolism. Every B2 supplement hands you raw material. The open question is whether the conversion from raw material to finished coenzyme is ever the limiting step, and whether supporting it changes anything you would notice.

The two enzymatic steps

Step 1: Riboflavin → FMN, via riboflavin kinase. Standard riboflavin has to clear this enzymatic step to become FMN. R5P is the activated, phosphorylated form of B2, the “activated form” the industry has taught you about. That advantage sits mainly at the intracellular level; as covered below, much oral R5P is dephosphorylated to riboflavin during absorption. Either way, it addresses only the first of two enzymatic steps.

Step 2: FMN → FAD, via FAD synthase. FAD synthase catalyzes FMN + ATP + Mg²⁺ → FAD + PPi. Two requirements are documented at the enzyme level: ATP as the energy substrate, and Mg²⁺ as a required cofactor coordinated with ATP (Frago et al., 2009; Bowers-Komro et al., 1989; Torchetti et al., 2011).

 

What each component contributes

Component 1: Riboflavin-5′-Phosphate, 137 mg (100 mg active, ≥73% riboflavin content). Supplies the activated flavin form of B2. Riboflavin from oral R5P appears in circulation within a few hours of ingestion (Zempleni et al., 1996). Because riboflavin is water-soluble and stored only in small amounts, daily intake is what sustains flavin availability (NIH ODS). This is the substrate layer.

Component 2: Magnesium bisglycinate, 278 mg. Provides the magnesium associated with the FMN-to-FAD step. This is a cofactor dose aimed at the enzyme’s requirement rather than a magnesium repletion dose, and it is set below the 350 mg/day Tolerable Upper Intake Level for supplemental magnesium established by the Food and Nutrition Board. The declared elemental magnesium per serving appears on the Supplement Facts panel. This is the cofactor layer.

Component 3: D-ribose, 250 mg (≥98% purity). D-ribose is the pentose that forms the sugar backbone of ATP, FAD, RNA, and DNA. In a randomized, double-blind crossover trial in eight trained men, muscle ATP returned to pre-training levels by 72 hours with ribose supplementation while remaining depressed on placebo, which the authors read as support for ribose availability being a limiting factor for the rate of ATP resynthesis. The same trial found no difference in mean or peak power output (Hellsten et al., 2004). That study used roughly 600 mg per kg of body weight per day, on the order of 42 g for a 70 kg adult, far above the 250 mg here. This is the ATP-substrate layer, included as substrate within the formula rather than at a studied standalone dose.

The design idea is synchronized delivery: substrate, cofactor, and ATP substrate arriving together in one capsule rather than depending on you juggling three separate supplements on a precise schedule.

What is the difference between vitamin B2 and FAD?

Vitamin B2 (riboflavin) is the dietary precursor. FAD (flavin adenine dinucleotide) is the active coenzyme form that performs biological functions in cells. Conversion runs in two steps: riboflavin kinase builds FMN from riboflavin, and FAD synthase converts FMN to FAD, drawing on magnesium and ATP.*

What does FAD do in the body for energy?

FAD is the active coenzyme form of vitamin B2 and serves as the prosthetic group in mitochondrial Complex II (succinate dehydrogenase). Complex I (NADH dehydrogenase) relies on FMN, the other B2-derived flavin, so vitamin B2 status is relevant to both entry points of the electron transport chain, one through FMN and one through FAD (Powers, 2003; NIH ODS). FAD is also a coenzyme for acyl-CoA dehydrogenases in fatty acid oxidation and for glutathione reductase.*

Within that framework, BioActive Vitamin B2™ supplies the activated flavin (R5P), a magnesium cofactor dose, and D-ribose, on the rationale that the pathway has what the enzymology describes. That is a formulation rationale, not a tested outcome of the finished product.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

What Do Riboflavin, Magnesium, and D-Ribose Do in Cellular Energy Metabolism?

Each of the three ingredients has an established role in normal energy metabolism. What follows is educational context for those roles, not a prediction of what you will personally experience.

What is riboflavin’s role in day-long energy metabolism?

Flavins derived from B2 function as coenzymes at the entry points of the electron transport chain, FMN in Complex I and FAD in Complex II. Because riboflavin is water-soluble and not stored in quantity, daily intake is what sustains flavin status (NIH ODS). That is the mechanistic reason consistency of intake matters for a nutrient like this, independent of any claim about how you will feel on a given afternoon.

Why is flavin-dependent metabolism discussed alongside cognitive demand?

The brain uses roughly 20% of the body’s energy output while making up about 2% of its mass (Raichle & Gusnard, 2002). Neurons are metabolically demanding cells, which is why flavin-dependent energy metabolism often comes up in the context of cognitive workload. This is background biochemistry about why the pathway matters generally, not a claim that this product improves cognition.

How is this different from caffeine?

Caffeine works by blocking adenosine receptors, which changes how tired you feel rather than contributing to cellular energy production. Riboflavin-derived flavins, by contrast, function as coenzymes within normal energy metabolism. This is a difference in mechanism, not a claim that this product will change your caffeine use or your sleep.*

How can you track your own response?

Because the finished formula has not been tested in a clinical trial, the honest guidance is to observe your own response rather than expect a scripted arc. If you would like to track it, log energy at set times daily and consider baseline and follow-up riboflavin-status testing with your healthcare provider.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

What Does the Evidence Show, and Where Does It Stop?

Enzyme-level (in vitro) evidence

The requirement for magnesium and ATP in the FMN-to-FAD reaction is characterized in enzyme studies. Frago et al. (2009, Journal of Biological Chemistry) states that both reactions of bacterial FAD synthetase require ATP and Mg²⁺. Bowers-Komro et al. (1989, Biochemistry) characterized the magnesium-dependent purified mammalian (rat-liver) enzyme. Torchetti et al. (2011, FEBS Journal) characterized recombinant human FAD synthase isoform 2, including its metal dependence. Karthikeyan resolved human riboflavin kinase with an intrinsically bound MgADP, supporting the ATP-magnesium mechanism of the upstream step.

This is enzyme-level evidence. It establishes what the pathway requires biochemically. It does not establish an energy outcome in healthy adults.

Is magnesium bisglycinate better absorbed than magnesium oxide?

The human evidence on magnesium form is genuinely mixed, and the two most-cited trials disagree.

Firoz and Graber (2001) measured fractional absorption of magnesium oxide at about 4% in normal volunteers, well below magnesium chloride, lactate, and aspartate, which were equivalent to one another. Their own conclusion was narrower than the way this study is usually quoted: that inorganic magnesium salts, depending on the preparation, may have bioavailability equivalent to organic magnesium salts.

Schuette et al. (1994) points the other way. In a double-blind randomized crossover trial in 12 patients with ileal resection, isotope-labeled magnesium diglycinate and magnesium oxide were absorbed at 23.5% and 22.8% respectively, not a significant difference for the group as a whole. The chelate did absorb substantially better in the four patients with the greatest impairment, reached peak enrichment about three hours earlier, and was better tolerated by every patient, and the authors concluded that some portion of the diglycinate is likely absorbed intact by way of a dipeptide transport pathway. Two caveats matter: oxide absorption in this trial was roughly five times the Firoz and Graber figure, and patients with ileal resection are not healthy adults.

Taken together, magnesium bisglycinate has not been compared head-to-head with oxide in a published absorption trial in healthy adults. The form used in this formula was selected for solubility and tolerability, and we are not claiming an absorption advantage over any other magnesium form.

Review-level evidence on riboflavin and energy metabolism

Powers (2003, American Journal of Clinical Nutrition) reviews riboflavin’s role in energy metabolism through flavin-dependent flavoproteins: FMN in Complex I and FAD in Complex II, plus acyl-CoA dehydrogenases and glutathione reductase. Ashoori and Saedisomeolia (2014, British Journal of Nutrition) reviews riboflavin’s antioxidant role through FAD-dependent glutathione reductase. Both are review-level sources.

Regulatory and manufacturing status

Riboflavin-5′-phosphate (sodium) is affirmed GRAS for food use under 21 CFR 184.1697. Magnesium is a lawful dietary ingredient; magnesium bisglycinate is used as an amino-acid chelate and is not among the magnesium salts affirmed under 21 CFR Part 184. D-ribose is the subject of GRAS Notice GRN 243, to which FDA responded with no questions for the notified conventional-food uses, and EFSA has separately concluded that intakes up to 36 mg/kg body weight per day are safe (EFSA, 2018). Manufacturing is under cGMP (21 CFR Part 111), and third-party testing documents potency at 95–105% of label claim and elemental contaminants against USP ⟨2232⟩ limits for dietary supplements. Certificates of Analysis are available on request.

How Does BioActive Vitamin B2™ Compare With Other Single-B2 Formulas?

A neutral comparison of what each option contains, by form and dose. This describes composition; it is not a claim that one option outperforms another.

 

 

 

High-dose plain riboflavin supplies more substrate but no cofactor support. Standard B-complex supplies a lower dose of the precursor form plus additional B vitamins you may not be targeting. Isolated R5P supplies the activated form without the magnesium cofactor. Caffeine works on adenosine signaling rather than on cellular energy production.

On the regulatory ceiling for riboflavin: the Food and Nutrition Board has not established a Tolerable Upper Intake Level for riboflavin, and no adverse effects have been reported from intakes up to 400 mg/day for at least three months. The same source cautions that the limited data available on riboflavin’s adverse effects does not mean that high intakes have no adverse effects, and the Board urges people to be cautious about consuming excessive amounts (NIH Office of Dietary Supplements).

Quality specifications for BioActive Vitamin B2™: R5P tested to ≥73% riboflavin content, magnesium supplied as magnesium bisglycinate, D-ribose at ≥98% purity, third-party tested to 95–105% of label claim, manufactured under cGMP (21 CFR Part 111).

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Frequently Asked Questions About B2 Cofactor Activation

I’ve tried R5P before and still had inconsistent results. Why would this be different? R5P covers the first of two enzymatic steps in FAD synthesis by supplying the activated flavin. The second step, FMN to FAD, draws on magnesium and ATP at the enzyme level (Frago et al., 2009). R5P-only products do not include that magnesium. BioActive Vitamin B2™ includes magnesium bisglycinate for this step, plus D-ribose as an ATP-related substrate. Whether that difference changes energy in healthy adults has not been tested in a finished-product trial, so the design is based on the enzymology, and individual responses vary.*

How is this better than taking R5P and magnesium separately? The rationale for a single capsule is coordination: the enzymatic requirement is for cofactor and substrate present together, not spread across the day. BioActive Vitamin B2™ combines R5P, magnesium bisglycinate, and D-ribose in one capsule. This is a convenience-and-coordination rationale, not a demonstrated outcome advantage over taking the same ingredients separately.*

I already take a separate magnesium supplement. Is the magnesium in this formula redundant? The magnesium here is a cofactor dose aimed at the FAD-synthesis step, not a comprehensive magnesium supplement, and it is set below the 420 mg Daily Value for magnesium and the 350 mg/day Tolerable Upper Intake Level for supplemental magnesium. Check the Supplement Facts panel for the exact amount per serving and count it toward your total daily magnesium intake alongside anything else you take. If you take separate magnesium for other reasons, this dose is intended to keep the B2 pathway’s cofactor from depending on timing. Because the formula contains magnesium, see the interaction note in the technical section.*

When should I expect to notice a difference? The finished formula has not been tested in a clinical trial, so there is no scripted timeline to offer. If you want to track your own response, log energy at set times daily and consider baseline and follow-up riboflavin-status testing with your healthcare provider. Consult your healthcare provider about your individual supplement protocol. Individual responses vary.*

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Bringing the Cofactor Step Into Your B2 Routine

Complete Cofactor Activation System™ is Triquetra’s formulation approach: pairing R5P with a magnesium cofactor dose and D-ribose in a single targeted B2 capsule. If you upgraded from standard riboflavin to R5P, this adds the magnesium and ATP-substrate layers that the second enzymatic step draws on.

The enzyme biochemistry behind the magnesium requirement is documented. The finished product has not been tested in a clinical trial. Quality is verified through third-party testing and cGMP manufacturing.

Learn More About BioActive Vitamin B2™

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Complete Technical Documentation

Full ingredient breakdown

Riboflavin-5′-Phosphate (R5P), 137 mg total, 100 mg active riboflavin

Molecular processing. R5P is the pre-phosphorylated, water-soluble sodium salt form of riboflavin-5′-phosphate, and it is the activated flavin form of B2. As documented below, orally administered R5P is largely dephosphorylated to free riboflavin during absorption, so its advantage sits mainly at the intracellular level. Riboflavin-5′-phosphate sodium is approximately 73% riboflavin by weight, which is why 137 mg of R5P supplies about 100 mg of riboflavin activity. Purity is verified separately by batch testing.

Circulation and status. Riboflavin from oral R5P appears in circulation within a few hours of ingestion (Zempleni et al., 1996). Because riboflavin is water-soluble and stored only in small amounts, daily intake is what sustains flavin availability (NIH ODS).

Dose rationale. 100 mg active provides 7,692% of the Daily Value (1.3 mg for adults and children 4 and older). That percentage should be read alongside a real limit: the body absorbs little riboflavin from single doses beyond 27 mg, stores only small amounts in the liver, heart, and kidneys, and excretes the excess in urine (NIH ODS). Riboflavin absorption from a single oral dose is saturable, so a large dose does not increase absorbed riboflavin proportionally (Zempleni et al., 1996). The 100 mg dose is intended to keep substrate availability from being the limiting factor rather than to maximize the absorbed amount, and a substantial share of it will not be absorbed.

Safety profile. The Food and Nutrition Board has not established a Tolerable Upper Intake Level for riboflavin, and no adverse effects have been reported from intakes up to 400 mg/day for at least three months. The same source cautions that the limited data available on riboflavin’s adverse effects does not mean that high intakes have no adverse effects, and the Board urges people to be cautious about consuming excessive amounts (NIH Office of Dietary Supplements). Riboflavin-5′-phosphate (sodium) is affirmed GRAS for food use under 21 CFR 184.1697. Riboflavin is a yellow, naturally fluorescent compound and the excess is excreted in urine (NIH ODS), so at intakes well above the Daily Value urine can look visibly bright yellow. That is a cosmetic consequence of excretion rather than a safety signal. Third-party testing per batch covers R5P tested to ≥73% riboflavin content and elemental contaminants against USP ⟨2232⟩ limits for dietary supplements.

Note on oral R5P absorption. Jusko & Levy (1967) and Zempleni et al. (1996) document that orally administered R5P undergoes intestinal dephosphorylation before absorption, with free riboflavin being the primary absorbed form in most individuals. R5P’s advantage is primarily at the intracellular level. The marketing claim of dramatically different blood absorption compared with riboflavin is more nuanced than typically represented.

Magnesium bisglycinate, 278 mg

Molecular processing. Magnesium bisglycinate is an amino-acid chelate in which magnesium is coordinated to two glycine molecules, forming an electrically neutral complex. Magnesium is declared on supplement labels as elemental magnesium, which is a smaller number than the weight of the ingredient it comes from, so the 278 mg above refers to the ingredient and the elemental amount per serving is the figure on the Supplement Facts panel. Some intact-dipeptide absorption has been reported for magnesium diglycinate in a 12-patient isotope trial, where the authors concluded that some portion is likely absorbed intact by way of a dipeptide transport pathway (Schuette et al., 1994); a specific PepT1 route is an inference, not demonstrated for this compound.

FAD synthesis role. FAD synthase (EC 2.7.7.2) is magnesium-dependent, and enzyme studies document Mg²⁺ coordinated with the ATP substrate in the adenylyl-transfer mechanism (Frago et al., 2009; Bowers-Komro et al., 1989).

Form selection. The comparative data are mixed. Firoz and Graber (2001) measured magnesium oxide fractional absorption at about 4% in normal volunteers, well below magnesium chloride, lactate, and aspartate. Schuette et al. (1994) found oxide and magnesium diglycinate absorbed almost identically (22.8% versus 23.5%) in 12 patients with ileal resection, with the chelate better tolerated and better absorbed only in the most impaired subgroup. Magnesium bisglycinate has not been compared head-to-head with oxide in a published absorption trial in healthy adults. The form was selected for solubility and tolerability, and no absorption advantage over other magnesium forms is claimed here.

Dose rationale. The magnesium in this formula is a cofactor dose targeting the FAD-synthesis step, intentionally not a comprehensive magnesium supplement. The declared elemental amount per serving is on the Supplement Facts panel and should be counted toward total daily magnesium intake. Users who take separate higher-dose magnesium can generally continue doing so, and should keep their combined intake in mind against the ceiling noted below.

Safety profile. The Tolerable Upper Intake Level for supplemental magnesium is 350 mg/day for adults, high supplemental doses can cause diarrhea, nausea, and abdominal cramping, and the forms most commonly reported to cause diarrhea are magnesium carbonate, chloride, gluconate, and oxide (NIH ODS). The magnesium in this formula is set below that ceiling and is supplied as bisglycinate rather than as any of those four salts. Individual GI tolerance still varies, this formula has not been tested for GI tolerability, and we do not claim it is free of GI effects for everyone.

D-ribose, 250 mg at ≥98% purity

Molecular processing. D-ribose is a naturally occurring pentose sugar that forms the structural backbone of ATP, FAD, RNA, and DNA. On its metabolic handling, the statement here is limited to what the cited human trial measured. In eight trained men, muscle ATP was still depressed 24 hours after a week of twice-daily sprint training and had recovered to pre-training levels by 72 hours with ribose supplementation but not with placebo. The authors interpreted this as support for muscle ribose availability being a limiting factor for the rate of ATP resynthesis (Hellsten et al., 2004).

FAD synthesis role. The FMN-to-FAD reaction uses ATP, and D-ribose supplies substrate for nucleotide synthesis. This completes the three-component design: activated flavin (R5P), magnesium cofactor, and an ATP-related substrate (D-ribose).

Dose context for informed users. The dose gap between this formula and the standalone ribose literature is large, and it is worth stating precisely. Hellsten et al. (2004) gave 200 mg per kg of body weight three times daily, roughly 42 g per day for a 70 kg adult, about 168 times the 250 mg here. Seifert et al. (2017) used 10 g per day, about 40 times this amount.

Results are mixed even at those doses. Hellsten et al. found faster muscle ATP recovery but no difference in mean or peak power output. Seifert et al. found maintained power output with lower perceived exertion and creatine kinase only in the lower-fitness subgroup, with no effect in fitter subjects, and did not measure ATP. Dunne et al. (2006), a double-blind randomized trial in 31 collegiate rowers, found that dextrose improved 2,000 m time-trial performance significantly more than ribose.

The 250 mg here is not a standalone ATP-recovery dose and should not be read as one. It is included as substrate within the cofactor system.

Safety profile. EFSA concluded that intakes up to 36 mg/kg body weight per day (about 2,500 mg for a 70 kg adult) are safe (EFSA, 2018), and 250 mg is well within that. D-ribose may transiently lower blood glucose (see interactions below). FDA responded with no questions to GRAS Notice GRN 243 for conventional-food uses. Purity of ≥98% is confirmed per batch.

The stress and magnesium relationship: context, not mechanism of action

Reviews of the stress and magnesium relationship suggest that stress may increase magnesium loss and that low magnesium status may in turn heighten stress reactivity, though the relationship has not been established as causal in humans (Pickering et al., 2020). No study shows stress-driven magnesium loss impairing FAD synthesis or producing measurable energy differences. This is general context for why magnesium status is discussed alongside B2, not an explanation for individual results.

Safety and drug interaction considerations

This product contains magnesium. Magnesium can reduce the absorption of oral bisphosphonates, tetracycline antibiotics, and quinolone antibiotics. The guidance is to separate doses by at least 2 hours for bisphosphonates, and to take those antibiotics at least 2 hours before or 4 to 6 hours after a magnesium-containing supplement (NIH ODS). FDA labeling for levothyroxine also directs that it be administered at least 4 hours before or after drugs known to interfere with its absorption, a list that includes magnesium-containing antacids. If you take any of these medications, talk with your healthcare provider or pharmacist about timing. D-ribose may transiently lower blood glucose, so if you take glucose-lowering medication, speak with your healthcare provider before use.*

Consult your healthcare provider about your full medication regimen. This product is not recommended as a substitute for a varied diet and healthy lifestyle. Consult your healthcare provider before starting any new supplement regimen, especially if you have a medical condition or take prescription medications.*

Extended FAQ

Does the R5P actually reach cells in its phosphorylated form? Jusko & Levy (1967) and Zempleni et al. (1996) document that orally administered R5P undergoes intestinal dephosphorylation before absorption in most individuals, so free riboflavin is the primary form absorbed. R5P’s advantage is primarily intracellular rather than at the point of blood absorption. The claim that R5P produces dramatically different blood absorption than riboflavin is more nuanced than typically represented.*

Can I take this while fasting or on an empty stomach? It can be taken with or without food. Riboflavin and its phosphate forms are water-soluble and do not require fat for absorption. Some people prefer a small meal to avoid mild GI sensitivity from magnesium, though this dose sits well under the 350 mg/day Tolerable Upper Intake Level for supplemental magnesium.*

Is EGRAC testing worth doing to confirm my B2 status? EGRAC is a widely used marker of riboflavin status, though the most appropriate cutoffs remain uncertain. Commonly used values are ≤1.2 adequate, 1.2–1.4 marginal, and >1.4 deficient. EGRAC is not valid in people with G6PD deficiency (NIH ODS). Ask your healthcare provider whether testing makes sense for you.*

What if I want to use this alongside MTHFR support supplements? Riboflavin status is relevant to the metabolism of several other B vitamins. The conversion of tryptophan to niacin requires FAD, the conversion of vitamin B6 to its coenzyme pyridoxal 5′-phosphate requires FMN, and severe riboflavin deficiency can impair the metabolism of other nutrients, especially other B vitamins, through diminished flavin coenzyme levels (NIH ODS). This formula can sit alongside methylfolate and methylcobalamin protocols. Consult your healthcare provider about your complete protocol, particularly if you are adjusting methylated B vitamin doses.*

What’s the shelf life and storage requirement? Store in a cool, dry location away from direct sunlight. Riboflavin and its phosphate forms are light-sensitive, which is why keeping the bottle out of direct light matters. See the product label for the specific expiration date; we do not make stability claims beyond that date.*

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

What This All Adds Up To

FAD synthase draws on magnesium-bound ATP to convert FMN to FAD, a requirement documented in enzyme studies. R5P covers the substrate side. Whether the cofactor side is a meaningful bottleneck for healthy adults, and whether pairing R5P with a magnesium cofactor dose and D-ribose changes anything you would notice, has not been tested in a clinical trial.

Complete Cofactor Activation System™ is Triquetra’s approach to that enzymology: R5P, a magnesium cofactor dose, and D-ribose in one targeted B2 capsule. The enzyme biochemistry is documented. The finished product is not clinically tested. Quality is verified through third-party testing and cGMP manufacturing.

Learn More AboutBioActive Vitamin B2™

Who BioActive Vitamin B2™ Is and Isn’t For

It may be a fit if:

• You take targeted supplements and want B2 in an activated form without the additional B vitamins in a standard B-complex.
• You have used riboflavin or R5P and want the magnesium and ATP-substrate layers that the second enzymatic step draws on, on that rationale.
• You value form and dose transparency, third-party testing, and cGMP manufacturing.

It may not be necessary if dietary riboflavin adequacy is confirmed and your energy status is satisfactory, if an existing B-complex works for you without side effects, or if budget favors other supplement priorities. Consult your healthcare provider about what fits your situation.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Scientific References & Citations

References support the ingredient-level and enzyme-level statements in this guide. The magnesium requirement of FAD synthesis is documented at the enzyme level; the finished formula has not been tested in a clinical trial.

Ashoori, M., & Saedisomeolia, A. (2014). Riboflavin (vitamin B₂) and oxidative stress: A review. British Journal of Nutrition, 111(11), 1985–1991. DOI: 10.1017/S0007114514000178 · PMID 24650639

Bowers-Komro, D. M., Yamada, Y., & McCormick, D. B. (1989). Substrate specificity and variables affecting efficiency of mammalian flavin adenine dinucleotide synthetase. Biochemistry, 28(21), 8439–8446. DOI: 10.1021/bi00447a025

Dunne, L., Worley, S., & Macknin, M. (2006). Ribose versus dextrose supplementation, association with rowing performance: A double-blind study. Clinical Journal of Sport Medicine, 16(1), 68–71. DOI: 10.1097/01.jsm.0000180022.44889.94 · Double-blind randomized trial, 31 women collegiate rowers, 10 g/day for 8 weeks. Dextrose improved 2,000 m time-trial performance significantly more than ribose (median 15.2 vs. 5.2 s; P = 0.031). A negative trial for ribose, included for balance.

European Food Safety Authority Panel on Nutrition, Novel Foods and Food Allergens. (2018). Safety of D-ribose as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal, 16(5), 5265. DOI: 10.2903/j.efsa.2018.5265

Firoz, M., & Graber, M. (2001). Bioavailability of US commercial magnesium preparations. Magnesium Research, 14(4), 257–262. PMID 11794633 · Urinary-excretion method in normal volunteers, ~21 mEq/day. Magnesium oxide fractional absorption ~4%; magnesium chloride, lactate, and aspartate significantly higher and equivalent to one another. The authors’ own conclusion is that inorganic magnesium salts, depending on preparation, may have bioavailability equivalent to organic salts. Bisglycinate was not tested.

Frago, S., Velázquez-Campoy, A., & Medina, M. (2009). The puzzle of ligand binding to Corynebacterium ammoniagenes FAD synthetase. Journal of Biological Chemistry, 284(11), 6610–6619. DOI: 10.1074/jbc.M808142200

Hellsten, Y., Skadhauge, L., & Bangsbo, J. (2004). Effect of ribose supplementation on resynthesis of adenine nucleotides after intense intermittent training in humans. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 286(1), R182–R188. DOI: 10.1152/ajpregu.00286.2003 · Randomized double-blind crossover, 8 trained men, 200 mg/kg body weight three times daily (about 42 g/day for a 70 kg adult, roughly 168 times the amount in this formula). Muscle ATP returned to pre-training levels by 72 h with ribose but remained depressed on placebo; mean and peak power output did not differ between ribose and placebo. Cited for ATP-resynthesis rate only; this study does not examine pentose-phosphate-pathway routing of ingested ribose.

Jusko, W. J., & Levy, G. (1967). Absorption, metabolism, and excretion of riboflavin-5′-phosphate in man. Journal of Pharmaceutical Sciences, 56(1), 58–62. DOI: 10.1002/jps.2600560112

Karthikeyan, S., Zhou, Q., Mseeh, F., Grishin, N. V., Osterman, A. L., & Zhang, H. (2003). Crystal structure of human riboflavin kinase reveals a beta barrel fold and a novel active site arch. Structure, 11(3), 265–273. DOI: 10.1016/s0969-2126(03)00024-8

National Institutes of Health, Office of Dietary Supplements. (2025). Magnesium: Fact sheet for health professionals. U.S. Department of Health and Human Services. NIH ODS Magnesium fact sheet

National Institutes of Health, Office of Dietary Supplements. (2025). Riboflavin: Fact sheet for health professionals. U.S. Department of Health and Human Services. NIH ODS Riboflavin fact sheet

National Institutes of Health, Office of Dietary Supplements. (2025). Vitamin B6: Fact sheet for health professionals. U.S. Department of Health and Human Services. NIH ODS Vitamin B6 fact sheet

Pickering, G., Mazur, A., Trousselard, M., Bienkowski, P., Yaltsewa, N., Amessou, M., Noah, L., & Pouteau, E. (2020). Magnesium status and stress: The vicious circle concept revisited. Nutrients, 12(12), 3672. DOI: 10.3390/nu12123672

Powers, H. J. (2003). Riboflavin (vitamin B-2) and health. American Journal of Clinical Nutrition, 77(6), 1352–1360. DOI: 10.1093/ajcn/77.6.1352

Raichle, M. E., & Gusnard, D. A. (2002). Appraising the brain’s energy budget. Proceedings of the National Academy of Sciences, 99(16), 10237–10239. DOI: 10.1073/pnas.172399499

Schuette, S. A., Lashner, B. A., & Janghorbani, M. (1994). Bioavailability of magnesium diglycinate vs magnesium oxide in patients with ileal resection. Journal of Parenteral and Enteral Nutrition, 18(5), 430–435. DOI: 10.1177/0148607194018005430 · Double-blind randomized crossover, 12 patients with ileal resection, 100 mg dose of ²⁶Mg-labeled chelate vs. MgO. Absorption 23.5% (chelate) vs. 22.8% (MgO), not significantly different for the group as a whole; chelate absorbed better in the 4 most impaired patients, reached peak enrichment about 3 h earlier, and was better tolerated by all patients. Note that MgO absorption here is roughly 5 times the Firoz and Graber figure, and that this is not a healthy-adult population.

Seifert, J. G., Brumet, A., & St Cyr, J. A. (2017). The influence of D-ribose ingestion and fitness level on performance and recovery. Journal of the International Society of Sports Nutrition, 14, 47. DOI: 10.1186/s12970-017-0205-8 · Randomized crossover trial, 26 healthy adults, 10 g/day D-ribose vs. dextrose; maintained power output and lowered perceived exertion and creatine kinase in the lower-fitness subgroup only, with no effect in the higher-fitness subgroup. ATP was not measured. Dose is roughly 40 times the amount in this formula.

Torchetti, E. M., Bonomi, F., Galluccio, M., Gianazza, E., Giancaspero, T. A., Iametti, S., Indiveri, C., & Barile, M. (2011). Human FAD synthase (isoform 2): A component of the machinery that delivers FAD to apo-flavoproteins. FEBS Journal, 278(22), 4434–4449. DOI: 10.1111/j.1742-4658.2011.08368.x

Wang, W., Kim, R., Jancarik, J., Yokota, H., & Kim, S.-H. (2003). Crystal structure of a flavin-binding protein from Thermotoga maritima. Proteins, 52(4), 633–635. DOI: 10.1002/prot.10353 · Supporting structural note; not an anchor for the human magnesium requirement.

Zempleni, J., Galloway, J. R., & McCormick, D. B. (1996). Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans. American Journal of Clinical Nutrition, 63(1), 54–66. DOI: 10.1093/ajcn/63.1.54

Regulatory sources

U.S. Food and Drug Administration. (2017). LEVO-T (levothyroxine sodium) tablets: Full prescribing information. FDA label 021342s023 · Cited for the instruction to administer levothyroxine at least 4 hours before or after drugs known to interfere with its absorption, including magnesium-containing antacids.

U.S. Food and Drug Administration. 21 CFR § 184.1697: Riboflavin-5′-phosphate (sodium). 21 CFR 184.1697

U.S. Food and Drug Administration. 21 CFR Part 111: Current good manufacturing practice for dietary supplements. 21 CFR Part 111

U.S. Food and Drug Administration. (2008). GRAS Notice No. GRN 243: D-ribose.

Verification note: every DOI and PubMed identifier in this list was resolved and matched against Crossref and PubMed records on August 18, 2026. Re-verify before publication if the reference list changes.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.